<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02342574</url>
  </required_header>
  <id_info>
    <org_study_id>F901318-01-02-14</org_study_id>
    <nct_id>NCT02342574</nct_id>
  </id_info>
  <brief_title>F901318 Multiple Ascending Dose Study</brief_title>
  <official_title>F901318 - A Phase I, Double-Blind, Placebo Controlled, Single and Multiple Ascending Intravenous Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>F2G Biotech GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hammersmith Medicines Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>F2G Biotech GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double blind, placebo controlled, parallel group ascending dose study evaluating single and&#xD;
      multiple (x8 days) dose levels of F901318 in groups of male healthy subjects with the&#xD;
      objective of defining a dosing schedule for phase ll clinical trials. F901318, a novel and&#xD;
      potent antifungal agent for the treatment of invasive aspergillosis, will be delivered&#xD;
      intravenously in a range of dosing schedules driven by pharmacokinetic evaluation in real&#xD;
      time. Safety and tolerability of those schedules will also be assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double blind, placebo controlled, ascending single and multiple intravenous dose, sequential&#xD;
      group study. This will be a study in two parts. In the first part, up to twenty four subjects&#xD;
      will complete the study in up to 3 cohorts (Groups A to C), each group consisting of 8&#xD;
      subjects, six of whom will receive active compound and two will receive placebo for eight&#xD;
      days. Each subject will be on study for approximately 7 weeks. Each subject will participate&#xD;
      in one treatment cohort only, residing at the Clinical Research Unit (CRU) from Day -1 (the&#xD;
      day before dosing) to Day 13 (120 hours post the last dose).&#xD;
&#xD;
      This first part (Part 1) will test doses already evaluated in the previous single ascending&#xD;
      dose study (F901318-01-01-14, 0.25-4 mg/kg given over 4 hours). The dose levels for the study&#xD;
      are expected to be 1.5, 3 and 4 mg/kg/day given as a four hour infusion once daily.&#xD;
&#xD;
      In the second part of the study (Part 2), doses higher than those previously evaluated may be&#xD;
      studied and/or different dosing schedules designed to deliver a maximum tolerated dose over&#xD;
      24 hours. If a dose level higher than those previously studied is chosen, there will be an&#xD;
      optional single dose studied initially for safety and pharmacokinetic profile (Part 2A),&#xD;
      followed about 14 days later in another group of subjects by exposure at that same dose level&#xD;
      over 8 consecutive days (Part 2B). These higher doses may be given in a once or twice daily&#xD;
      dosing schedule. Six subjects will receive active compound and two will receive placebo in&#xD;
      both the single dose and multiple dose cohorts. The single dose cohorts will receive study&#xD;
      drug in a sentinel group design in which two subjects receive study drug (one active and one&#xD;
      placebo) on the first day and the rest of the group one day later. There will be a review of&#xD;
      safety data by the Principal Investigator and the Medical Monitor after the first two&#xD;
      subjects have been dosed and before the last six subjects are dosed in each cohort in part&#xD;
      2A.&#xD;
&#xD;
      In Part 2, up to forty-eight subjects will complete the study in up to 6 cohorts (Part 2A,&#xD;
      Groups D1 to F1, single day dosing, and Part 2B, Groups D2 to F2 eight days' dosing).&#xD;
      Subjects in Parts 1 and 2B will be on the study for approximately 7 weeks and Part 2A for&#xD;
      approximately 8 weeks. Each subject will participate in one treatment cohort only, residing&#xD;
      at the Clinical Research Unit (CRU) from Day -1 (the day before dosing) to Day 6 (120 hours&#xD;
      after the single dose in Parts 1 and 2A) and from Day -1 (the day before dosing) to Day 13&#xD;
      (120 hours after the first dose in Part 2B). The proposed total daily dose levels for Part 2&#xD;
      will be up to 10 mg/kg/day given either once daily or in two split daily doses. The duration&#xD;
      of the infusions will be between 2 and 24 hours which may include a loading dose to achieve&#xD;
      therapeutic plasma concentrations as quickly as possible.&#xD;
&#xD;
      All subjects will return for a post-study visit 8 to 10 days after the last dose of study&#xD;
      medication.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety: adverse events</measure>
    <time_frame>13 days</time_frame>
    <description>adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetics AUC</measure>
    <time_frame>13 days</time_frame>
    <description>area under concentration time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetics Cmin</measure>
    <time_frame>13 days</time_frame>
    <description>drug level in blood 24 hours after dosing</description>
  </secondary_outcome>
  <number_of_arms>18</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Invasive Aspergillosis</condition>
  <arm_group>
    <arm_group_label>A active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six subjects receiving F901318 1.5 mg/kg intravenously for eight days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two subjects receiving F901318 placebo intravenously for eight days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six subjects receiving F901318 3 mg/kg intravenously for eight days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two subjects receiving F901318 placebo intravenously for eight days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six subjects receiving F901318 4 mg/kg intravenously for eight days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two subjects receiving F901318 placebo intravenously for eight days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D1 active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six subjects dosed for one day with F901318 intravenously dose to be determined</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D1 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two subjects receiving F901318 placebo intravenously for one day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E1 active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six subjects dosed for one day with F901318 intravenously dose to be determined</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E1 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two subjects receiving F901318 placebo intravenously for one day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F1 active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six subjects dosed for one day with F901318 intravenously dose to be determined</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F1 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two subjects receiving F901318 placebo intravenously for one day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D2 active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six subjects dosed for eight days with F901318 intravenously dose to be determined</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D2 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two subjects receiving F901318 placebo intravenously for eight days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E2 active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six subjects dosed for eight days with F901318 intravenously dose to be determined</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E2 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two subjects receiving F901318 placebo intravenously for eight days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F2 active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six subjects dosed for eight days with F901318 intravenously dose to be determined</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F2 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two subjects receiving F901318 placebo intravenously for eight days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F901318</intervention_name>
    <description>Administration of active compound</description>
    <arm_group_label>A active</arm_group_label>
    <arm_group_label>B active</arm_group_label>
    <arm_group_label>C active</arm_group_label>
    <arm_group_label>D1 active</arm_group_label>
    <arm_group_label>D2 active</arm_group_label>
    <arm_group_label>E1 active</arm_group_label>
    <arm_group_label>E2 active</arm_group_label>
    <arm_group_label>F1 active</arm_group_label>
    <arm_group_label>F2 active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administration of placebo</description>
    <arm_group_label>A placebo</arm_group_label>
    <arm_group_label>B placebo</arm_group_label>
    <arm_group_label>C placebo</arm_group_label>
    <arm_group_label>D1 placebo</arm_group_label>
    <arm_group_label>D2 placebo</arm_group_label>
    <arm_group_label>E1 placebo</arm_group_label>
    <arm_group_label>E2 placebo</arm_group_label>
    <arm_group_label>F1 placebo</arm_group_label>
    <arm_group_label>F2 placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects will be males of any ethnic origin between 18 and 45 years of age and&#xD;
             weighing 60-100 kg inclusive&#xD;
&#xD;
          2. Subjects must be in good health, as determined by a medical history, physical&#xD;
             examination, 12-lead electrocardiogram (ECG) and clinical laboratory evaluations&#xD;
             (congenital non haemolytic hyperbilirubinaemia is acceptable)&#xD;
&#xD;
          3. Subjects will have given their written informed consent to participate in the study&#xD;
             and to abide by the study restrictions&#xD;
&#xD;
          4. Subjects must have ophthalmology assessments within the normal limits at screening.&#xD;
             This includes normal Meibomian gland function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Male subjects who are not willing to use appropriate contraception (such as a condom)&#xD;
             during the study and until follow up&#xD;
&#xD;
          2. Subjects who have received any prescribed systemic or topical medication within 14&#xD;
             days of dosing with study drug unless in the opinion of the Investigator and the&#xD;
             Medical Monitor the medication will not interfere with the study procedures or&#xD;
             compromise safety&#xD;
&#xD;
          3. Subjects who have used any non-prescribed systemic or topical medication (including&#xD;
             herbal remedies) within 7 days of dosing with study drug (with the exception of&#xD;
             vitamin/mineral supplements and paracetamol) unless in the opinion of the Investigator&#xD;
             and the Medical Monitor the medication will not interfere with the study procedures or&#xD;
             compromise safety&#xD;
&#xD;
          4. Subjects who have received any medications, including St John's Wort, known to&#xD;
             chronically alter drug absorption or elimination processes within 30 days of dosing&#xD;
             with study drug unless in the opinion of the Investigator and the Medical Monitor the&#xD;
             medication will not interfere with the study procedures or compromise safety&#xD;
&#xD;
          5. Subjects who are still participating in a clinical study (e.g. attending follow-up&#xD;
             visits) or who have participated in a clinical study involving administration of an&#xD;
             investigational drug (new chemical or biological entity) in the past 3 months since&#xD;
             the last dose.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frans van den Berg, MB ChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hammersmith Medicines Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hammersmith Medicines Research</name>
      <address>
        <city>London</city>
        <state>UK</state>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>January 15, 2015</study_first_submitted>
  <study_first_submitted_qc>January 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2015</study_first_posted>
  <last_update_submitted>September 16, 2016</last_update_submitted>
  <last_update_submitted_qc>September 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspergillosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olorofim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

